<DOC>
	<DOCNO>NCT01197209</DOCNO>
	<brief_summary>This phase I neoadjuvant gene therapy follow prostatectomy , open-label , dose-escalation trial prostate cancer patient high risk local recurrence radical prostatectomy . Patients enter trial Prostate Cancer Clinical stage T1c , T2 T3 Gleason Score 7 ( 4+3 ) 10 time enrollment . Patients receive three 1 mL injection ( 3 mL total volume ) Ad-REIC/Dkk-3 prostate prior undergoing radical prostatectomy . Three patient treat dose level unless dose-limiting toxicity ( DLT ) observe MFD ( define 1 x 10e12 vp/treatment ) achieve expansion 6 patient MTD MFD .</brief_summary>
	<brief_title>Neoadjuvant Study In-situ REIC/Dkk-3 Prostate Cancer</brief_title>
	<detailed_description>This phase I neoadjuvant gene therapy follow prostatectomy , open-label , dose-escalation trial prostate cancer patient high risk local recurrence radical prostatectomy . Patients enter trial Prostate Cancer Clinical stage T1c , T2 T3 Gleason Score 7 ( 4+3 ) 10 time enrollment . Patients receive three 1 mL injection ( 3 mL total volume ) Ad-REIC/Dkk-3 prostate transrectal ultrasound-guidance ( TRUS ) , patient undergo radical prostatectomy four week injection . Patients receive treatment one three dose level sequential dose-escalating design . Three patient treat dose level unless dose-limiting toxicity ( DLT ) observe MFD ( define 1 x 10e12 vp/treatment ) achieve . Enrollment proceed next dose level 0 3 patient experience DLT ; one first 3 patient experience DLT , three additional patient enrol second patient experience DLT ( defines toxic dose ) six total patient treat dose level , whichever come first . If second DLT experience within cohort , dose escalation may continue . Additional patient enrol minimum 14 day treatment first patient cohort ( sentinel patient ) . If 2 DLTs observe within cohort , enrollment cohort cease dose level immediately precede dose determine MTD . If 2 non-lethal DLTs observe Cohort 1 , low dose cohort ( Cohort -1 ) may initiate . Once MTD define , additional 3-6 patient may enrol dose level evaluate safety MTD . Patients undergo scheduled radical prostatectomy approximately 4 week Ad-REIC/Dkk-3 injection . The prostate tissue remove retained patient treat MTD , assess REIC expression evidence apoptosis TUNEL staining .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Male age 20 75 year ( inclusive ) histologically document clinically localize , adenocarcinoma prostate schedule undergo radical prostatectomy . 2 . Patient clinical stage T1c , T2 T3 Primary Gleason score 4 [ total Gleason score 7 ( 4+3 ) 10 ] time assessment trial . 3 . Recent ( ≤ 3 month prior study entry ) negative bone scan CT scan abdomen/pelvis . 4 . Life expectancy least 10 year . 5 . In good general health , free clinically significant illness disease ( determined medical/surgical history , physical examination , weight , 12lead ECG , clinical laboratory test ) 6 . Appropriate surgical candidate radical prostatectomy performance status ≤ 2 ( Zubrod scale ) 7 . Patients adequate bone marrow function define absolute peripheral granulocyte count ≥ 1,500 platelet count ≥ 100,000 , adequate hepatic function total bilirubin ≤ 1.5 mg/dl ALT &lt; 4x upper limit normal , adequate renal function define serum creatinine ≤ 2.0 mg/dl 8 . Body Mass Index ≥ 18 ≤ 35 kg/m2 9 . Patients must normal coagulation profile ( PT , PTT ) history substantial noniatrogenic bleeding diatheses . Use anticoagulant limit local use ( control central line patency ) . 10 . Patient willing refrain sexual activity agree use barrier contraceptive device ( e.g . condom ) treatment AdREIC/Dkk3 prostatectomy operation . 11 . Patients must sign informed consent indicate aware investigational nature study , keep policy institution . 1 . Previous current hormonal treatment , chemotherapy , radiation therapy , immunotherapy investigational status drug within past 4 week . 2 . Unable tolerate transrectal ultrasound . 3 . Patients appropriate surgical candidate radical prostatectomy base evaluation coexistent medical disease compete cause death . 4 . Patients uncontrolled cardiac , hepatic , renal neurologic/psychiatric disorder eligible . 5 . Patients HIV positive chronic hepatitis B C infection eligible ( possible immune effect condition ) . 6 . Patients clinical history primary secondary immunodeficiency , autoimmune disease patient take immunosuppressive drug corticosteroid continuously &gt; 4 month [ &gt; 5 mg hydrocortisone/day ] ineligible . ( The experimental treatment evaluate protocol depends intact immune system . Patients decrease immune competence may less responsive experimental treatment susceptible toxicity . ) 7 . As result medical review , physical examination , Principal Investigator ( medically qualify nominee ) considers subject unfit study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostatectomy</keyword>
	<keyword>Postectomy</keyword>
	<keyword>Oncology</keyword>
	<keyword>REIC</keyword>
	<keyword>Dikkoff</keyword>
	<keyword>Apoptosis</keyword>
</DOC>